|Address||Hôpital Henri Mondor Créteil
51 avenue du Maréchal de Lattre de Tassigny
94000 Créteil, France
|Platforms||ATMP & Biological, Imaging & Tracing, Small Molecules|
|Tags||Clinical Trials, Gene and cell therapy, Parkinson's and Huntington's disease|
The Henri Mondor Hospital is a set of more than 1,300 beds and more than 120 day hospital places covering the majority of short stay medical and surgical disciplines. For its size, it is the second hospital of the Assistance Publique after the Pitié-Salpêtrière hospital.
Research and Neurodegenerative Diseases
At Henri Mondor Hospital, clinical research in the field of neurodegenerative diseases started in 1990 with graft projects in Parkinson’s disease. Since then, biotherapies remained at the heart of the specificity of neuroscientific research at Henri Mondor university hospital with world-class cell and gene therapy studies in Parkinson’s and Huntington’s diseases. These highly innovative projects benefit from the expertise of the Functional Neurosurgery team and from collaborations established for more than 25 years with CEA teams (Service Hospitalier Frédéric Joliot and MIRCEN). In the field of neurodegenerative diseases, our teams have published 60 papers over the last 5 years.
The center is integrated into the ns-park national network (Neurosciences Parkinson) which coordinates multi-centric therapeutic research projects at national level.
An Expert Centre for Parkinson’s disease with a cohort of over 1600 patients and the national reference center for Huntington’s disease is located endow Henri Mondor hospital.
Several Inserm research teams, grouped in the IMRB are working on neurological and psychiatric diseases.
This institute is part of NeurATRIS, the French part of EATRIS.